Benefits | Risks | ||||||
---|---|---|---|---|---|---|---|
Hemoglobin A1c | Weight and blood pressure | Heart failure hospitalizations | Cardiovascular events | Progression of renal disease | Fracture, amputation | Genital infection | |
Empagliflozin | Decrease | Decrease | Decrease | Decrease | Decrease | No change | Increase |
Canagliflozin | Decrease | Decrease | Decrease | No change | Decrease | No changea | Increase |
Dapagliflozin | Decrease | Decrease | Decrease | No change | Decrease | No change | Increase |
Ertugliflozin | Decrease | Decrease | Decrease | No change | No change | No change | Increase |
↵a Changed from “increases risk” to “no change” after the removal of the black box warning by the US Food and Drug Administration.